Table 1.

Patient demographics

VariableCategoriesEvaluable patients (N = 231)
Age at BaselineAverage ± SD70 ± 9
(n = 231)Median (range)70 (45-92)
Race:White209 (90%)
Black17 (7%)
Hispanic3 (1%)
Asian2 (1%)
Baseline ECOG0101 (44%)
1100 (43%)
221 (9%)
Unknown9 (4%)
Gleason score≤518 (8%)
628 (12%)
763 (27%)
845 (20%)
≥954 (23%)
Unknown23 (10%)
Line of cytotoxic therapy1st154 (67%)
2nd38 (16%)
≥3rd39 (17%)
Taxotere used inNo67 (29%)
current therapy lineYes162 (70%)
Unknown2 (1%)
Bone metastasisNegative20 (8%)
Positive207 (90%)
Unknown4 (2%)
Visceral metastasisNo141 (61%)
Yes89 (39%)
Unknown1 (0%)
Baseline PSA (ng/mL)Average ± SD546.9 ± 1,615.9
Centrally determined (n = 231)Median (range)144 (1.9-17,800)
Baseline hemoglobin (g/dL)Average ± SD12.3 ± 1.6
Site determined (n = 221)Median (range)12.4 (8.2-15.7)
Baseline alkaline phosphatase (IU/mL)Average ± SD235 ± 271
Centrally determined (n = 223)Median (range)144 (39-2,215)
Baseline LDH (IU/mL)Average ± SD293 ± 228
Centrally determined (n = 219)Median (range)224 (103-2,092)
Baseline albumin (g/dL)Average ± SD3.9 ± 2.6
Site determined (n = 214)Median (range)3.8 (2.1-41.0)
  • Abbreviations: ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase.